• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection

    Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection

  2. Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

    Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

  3. Global Hypertrophic Cardiomyopathy Therapeutics Market to Grow at a CAGR of 1.8%, 2017-2021 with AstraZeneca, Merck, Pfizer & Sanofi Dominating - Research and Markets

    Global Hypertrophic Cardiomyopathy Therapeutics Market to Grow at a CAGR of 1.8%, 2017-2021 with AstraZeneca, Merck, Pfizer & Sanofi Dominating - Research and Markets

  4. Global Acute Respiratory Failure Clinical Trials Review: H1, 2017 Report - Research and Markets

    Global Acute Respiratory Failure Clinical Trials Review: H1, 2017 Report - Research and Markets

  5. The Black Church & HIV Initiative Launches Newly Updated Pastoral Resources for Faith Leaders, Empowering Them to Incorporate HIV into Ministry

    The Black Church & HIV Initiative Launches Newly Updated Pastoral Resources for Faith Leaders, Empowering Them to Incorporate HIV into Ministry

  6. Why biotech stocks are a healthy bet in sickly broader market

    Why biotech stocks are a healthy bet in sickly broader market

  7. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  8. Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - ...

    Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - Research and Markets

  9. Global $69.2 Billion Antiviral Drugs (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor) Market 2014-2025 - Research and Markets

    Global $69.2 Billion Antiviral Drugs (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor) Market 2014-2025 - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.